Retatrutide vs tirzepatide: which produces more weight loss?

The Headline Numbers

Cross-trial comparison (not head-to-head, but closest we have):

• Tirzepatide SURMOUNT-1 — mean weight loss 22.5% over 72 weeks at 15 mg
• Retatrutide Phase 2 — mean weight loss 24.2% over 48 weeks at 12 mg
• Retatrutide Phase 3 higher-dose cohorts — reports of up to 28.7% mean weight loss

Retatrutide appears to produce greater absolute weight loss, and it does so faster — 24% at 48 weeks compares to tirzepatide's 22.5% at 72 weeks.

Mechanism Comparison

Tirzepatide — Dual Agonist

• GLP-1 receptor agonist (appetite suppression, satiety, glycemic control)
• GIP receptor agonist (insulin enhancement, fat metabolism, GI tolerability)
• Two mechanisms

Retatrutide — Triple Agonist

• GLP-1 receptor agonist (same as above)
• GIP receptor agonist (same as above)
• Glucagon receptor agonist (increases resting energy expenditure, enhances fat oxidation)

The glucagon arm is retatrutide's key differentiator. Glucagon is classically thought of as the blood-sugar-raising hormone, but its receptor activity also increases energy expenditure. Retatrutide's design balances the glucose-raising and energy-expending effects of glucagon against its counterbalancing GLP-1 glucose-lowering effect, resulting in net benefit.

Availability Comparison

Tirzepatide

• FDA approved as Zepbound (obesity) and Mounjaro (T2D)
• Available by prescription at retail pharmacies
• Compounded tirzepatide available through telehealth (regulatory status evolving)
• Insurance coverage widespread

Retatrutide

• Not FDA approved
• Not available by prescription
• Legitimate access only through clinical trials
• Research-chem vendor product is not FDA-regulated and safety cannot be assured
• Expected approval 2027

Side-Effect Comparison

Both share the GLP-1 class profile: GI-dominant side effects (nausea, vomiting, diarrhea, constipation). Notable differences:

Tirzepatide Side Effects

• Generally well tolerated at 5–10 mg doses
• Intensified GI effects at 12.5 mg and 15 mg
• Sulfur burps common at higher doses
• Heart rate increase of ~3–5 bpm typical

Retatrutide Side Effects (Trial Data)

• Similar GI profile but potentially more intense at high doses
• Slightly more pronounced heart rate increase (3–8 bpm)
• Glucagon component can affect blood sugar in susceptible patients
• Long-term safety data still accumulating

Dosing Comparison

Tirzepatide

• Titration from 2.5 mg to 15 mg weekly over 20+ weeks
• Once weekly subcutaneous
• Maintenance typically 10 mg or 15 mg

Retatrutide (Trial Protocols)

• Titration from 2 mg to 12 mg (sometimes higher) weekly over 16+ weeks
• Once weekly subcutaneous
• Commercial maintenance dose TBD at FDA approval

Who Should Wait for Retatrutide

• Patients at or near weight-loss goals with tirzepatide — no urgency
• Patients tolerating tirzepatide well — switching risks GI profile changes
• Anyone with specific contraindications to glucagon-pathway activation

Who Might Benefit More From Retatrutide Once Available

• Patients with inadequate response to maximum tirzepatide doses
• Patients with severe MASH or cardiometabolic disease (where glucagon-driven fat oxidation may add value)
• Patients with very high BMI needing larger absolute weight loss

Bottom Line

Retatrutide will likely raise the efficacy ceiling for weight-loss pharmacotherapy once approved. For now, tirzepatide remains the most effective approved option. Patients should not wait indefinitely for retatrutide — the health benefits of current treatment compound, and 2027 is a long time if you're postponing care.

See retatrutide and tirzepatide guides.